- Home
- RACC vs KLRS Comparison
RACC vs KLRS Comparison
Compare RACC & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RACC | KLRS |
|---|---|---|
| Founded | 2026 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.8M | 92.8M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RACC | KLRS |
|---|---|---|
| Price | $10.55 | $2.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $18.71 |
| AVG Volume (30 Days) | ★ 146.7K | 50.3K |
| Earning Date | N/A | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.62 | $2.81 |
| 52 Week High | $33.50 | $11.88 |
Technical Indicators
Market Signals| Indicator | RACC | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 24.74 | 26.31 |
| Support Level | $10.44 | N/A |
| Resistance Level | $12.38 | $4.37 |
| Average True Range (ATR) | 0.35 | 0.15 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 55.50 | 18.71 |
Price Performance
Historical ComparisonAbout RACC Research Alliance Corporation III Class A Ordinary Shares
Research Alliance Corporation III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.